What Susceptible and Resistant Mean on a Culture Report

The short version

When a culture report calls an organism "susceptible" or "resistant," it is not naming a fixed property of the microbe. It is reporting a prediction: whether a drug concentration your body can realistically achieve is likely to control that specific isolate. Two ingredients produce that word, a laboratory measurement called the minimum inhibitory concentration (MIC) and a clinical breakpoint that already carries assumptions about dose and drug exposure. Shift those assumptions, and the same MIC can move from susceptible to resistant without the bacterium changing at all.

The MIC is a measurement, not a decision

The MIC is the lowest concentration of an antibiotic, usually written in milligrams per liter, that prevents visible growth of the organism under standardized laboratory conditions. It is a number, and a number alone does not sort a drug into susceptible or resistant. An MIC of 2 for one antibiotic and 0.5 for another does not mean the second is "stronger," because each drug reaches different concentrations in blood and tissue and each sits on its own scale. The MIC becomes clinically meaningful only once it is compared against a threshold chosen for that drug, that organism, and that type of infection.

The breakpoint does the translating

That threshold is the breakpoint, and setting one is deliberate work rather than a round number. Committees begin with the wild-type MIC distribution, the range of values seen in organisms carrying no acquired resistance, which anchors the epidemiological cutoff. They layer on pharmacokinetics and pharmacodynamics: how the drug rises and falls in the body, which exposure measure predicts killing, and, through Monte Carlo simulation, the probability that a given dose reaches that target across a population. A common approach sets the pharmacologic breakpoint near the highest MIC at which a large majority of patients would still attain the pharmacodynamic target on a defined regimen. Clinical outcome data, where they exist, are then used to check the number against reality. The idea running through the whole process is easy to state: it is the dose that matters.

"Susceptible" is a statement about exposure

Because a breakpoint has a dose and a body built into it, the category on the report is really a claim about exposure. EUCAST, the European committee, made this explicit in 2019 when it rewrote its definitions. In the current wording, an organism is "Susceptible, standard dosing regimen" when there is a high likelihood of therapeutic success using a standard dose, "Susceptible, increased exposure" when success is likely because exposure is increased by adjusting the dosing regimen or by the drug concentrating at the site of infection, and "Resistant" when failure is likely even with increased exposure. Read carefully, the middle category is not a warning to avoid the drug. It says the drug can still work if the concentration is pushed higher, for instance with a larger or more frequent dose.

CLSI, the standards body whose tables most US laboratories follow, reaches the same idea through a different label. Alongside susceptible, intermediate, and resistant, it uses "susceptible-dose-dependent" for certain drug and organism pairs, cefepime against Enterobacterales among them, to signal that a higher dosing strategy is what makes the result meaningful.

Site of infection matters for the same reason. A drug that concentrates heavily in urine can clear a bladder infection at an MIC that would predict failure in the bloodstream or spinal fluid, which is why some reports carry separate urinary breakpoints.

Why CLSI and EUCAST can disagree

Hand the same MIC to both committees and they will sometimes return different words. In a 2023 analysis published in Cureus, Gaur and colleagues compared CLSI and EUCAST interpretations across a panel of organisms and found agreement ranging from almost perfect for meropenem to only slight for fosfomycin. The disagreements are not errors. They follow from different assumptions about the dose a clinician will use, different choices of pharmacodynamic target, differences in laboratory method such as whether faint inner colonies are read or ignored, and different category structures. The practical consequence is that switching a laboratory from one system to the other can raise or lower the reported susceptibility rate for a drug while the organisms sitting in the freezer are unchanged.

Breakpoints also move through time

The thresholds are revised as evidence accumulates. In the United States, the 21st Century Cures Act created a streamlined pathway for the Food and Drug Administration to recognize breakpoints, and the agency now maintains a public list, updated at least twice a year, that for most drugs recognizes the CLSI standards. Cefepime is a well-known example of a breakpoint that was lowered after data showed standard dosing was failing at MICs previously called susceptible. A result labeled "susceptible" under an older table could read as "resistant" under the current one, again with no change in the microbe.

So what does the word actually promise

"Susceptible" is best read as a probability, not a guarantee, and a probability resting on several assumptions stacked together: the measured MIC, the breakpoint applied, the dose that breakpoint assumes, the site being treated, and which committee's table your laboratory uses. "Resistant" carries the mirror image, a prediction that even a pushed dose is unlikely to succeed. Neither word describes the organism in isolation. Each describes the meeting point between an organism and an achievable drug exposure.

This article is educational and is not medical advice; treatment decisions belong to you and the clinician managing your care.